Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EloraTZP in obesity or overweight and type 2 diabetes
NCT07881458Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2026
- Primary completion
- Oct 2029
- Countries
- 10
01
Overview
Phase 3, randomised trial of eloralintide in obesity and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change from Baseline in Body Weight at 100 weeks. Started Oct 2026; status: recruiting.
02
Drugs
eloralintide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07881458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07881458.